Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Net Income | -- | -- | -16.30M | -24.67M | |
| Total Depreciation and Amortization | -- | -- | -- | 344.00K | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -- | -- | -1.40M | 665.00K | |
| Change in Net Operating Assets | -- | -- | -2.24M | -400.00K | |
| Cash from Operations | -- | -- | -19.94M | -24.06M | |
| Capital Expenditure | -- | -- | -353.00K | -529.00K | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | 29.00K | 28.00K | |
| Cash from Investing | -- | -- | -324.00K | -501.00K | |
| Total Debt Issued | -- | -- | 7.93M | 7.93M | |
| Total Debt Repaid | -- | -- | -319.00K | -463.00K | |
| Issuance of Common Stock | -- | -- | 48.00K | 26.00M | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -355.00K | -1.51M | |
| Cash from Financing | -- | -- | 7.31M | 31.96M | |
| Foreign Exchange rate Adjustments | -- | -- | -1.35M | -1.49M | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -- | -- | -14.31M | 5.91M | |